Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362920 · ClinicalTrials.gov registry record
Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 300
- Enrollment target
NCT01362920 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 300 participants.
The verdict
NCT01362920 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
In 2005, the Food and Drug Administration (FDA) approved procalcitonin in conjunction with other laboratory markers to aid in the risk assessment of critically ill patients with severe infection (sepsis). Although considerable literature exists regarding the usefulness of Procalcitonin (PCT) as a marker of sepsis, there are still potential uses for PCT measurements that are not yet explored and its value among the critically ill patients remains unclear. This study seeks to better understand the usefulness of measuring PCT values in patients admitted to the Medical ICU for a variety of reasons and in particular with severe infection (sepsis).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362920
The ClinicalTrials.gov registry entry for NCT01362920 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01362920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362920 about?
NCT01362920 is a clinical study titled "Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients". In 2005, the Food and Drug Administration (FDA) approved procalcitonin in conjunction with other laboratory markers to aid in the risk assessment of critically ill patients with severe infection (sepsis). Although considerable literature exists regarding the usefulness of Procalcitonin (PCT) as a ma...
What is the current status of trial NCT01362920?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2011-04. Estimated completion is 2012-11.
Who is sponsoring clinical trial NCT01362920?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.